Anti-CD30 CAR T cells

also known as CART30

Developed for: Hodgkins lymphoma · anaplastic large cell lymphoma · angioimmunoblastic T-cell lymphoma · lymphoma · adult T-cell leukemia/lymphoma · B-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classical Hodgkin lymphoma · non-Hodgkin lymphoma · peripheral T-cell lymphoma, not otherwise specified
+1 more
· primary mediastinal large B-cell lymphoma
Investigated by: Affiliated Hospital of Nantong University · Chinese PLA General Hospital · Peking University · Shanghai First Song Biotechnology Co., LTD · Shanghai First Song Therapeutics Co., Ltd · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
+3 more
· University of Florida · Wuhan Bio-Raid Biotechnology Co, Ltd. China · Zhejiang University

20142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 02 trials
Phase 0	NCT06756321	Sep 2023 → Mar 2025 overdue	leukemia, lymphoma	Affiliated Hospital of Nantong University	Recruiting	No outcome recorded
Phase 0	NCT05208853	Feb 2022	B-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classical Hodgkin lymphoma, Hodgkins lymphoma, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma +2	Zhejiang University	Unknown	No outcome recorded
Phase 11 trial
Phase 1	NCT04008394	Jul 2019 → Jul 2022	Hodgkins lymphoma, adult T-cell leukemia/lymphoma, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Unknown	No outcome recorded
Phase 1/22 trials
Phase 1/2	NCT02259556	Oct 2014 → Oct 2018 overdue	Hodgkins lymphoma, non-Hodgkin lymphoma	Chinese PLA General Hospital	Recruiting	No outcome recorded
Phase 1/2	NCT02274584	Mar 2014 → Oct 2016	lymphoma	Peking University	Unknown	No outcome recorded

Every value below carries the sentence it was read from. 5 sources stand behind the page.

Field	Value	Cited text
Known as	Anti CD30 CAR T Cells	“Anti CD30 CAR T Cells” NCT05208853 ↗ 3 NCT02274584 ↗ NCT06756321 ↗ NCT04008394 ↗
Known as	CART30	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02259556 ↗
Action	Deplete	“effective killing of CD30 target cells” NCT02274584 ↗
Modality	Cell therapy	“Chimeric antigen receptor-modified T cells (CART) holds great promise for treatment of tumors.” NCT02259556 ↗
Route	Intravenous	“infusions of CART30 cells into the vein” NCT02259556 ↗